Drug Importation in New Hampshire: An Overview
New Hampshire submitted an application for its state importation program in April 2021. The FDA rejected the application in November 2022 because it did not identify a Canadian wholesaler that would provide the drugs.
In January 2020, the New Hampshire legislature introduced SB685, which would require the New Hampshire Department of Health and Human Services to design a wholesale importation program for prescription drugs from Canada by or on behalf of the state and obtain federal approval for the program. In June 2020, SB685 was added to HB1280, which included several other prescription drug initiatives. The bill was signed into law in July 2020.
How should we evaluate this program?
The program hasn't started yet, or even been designed, so there's no way to measure whether it saved money or kept patients safe, both promises made at the time of passage. However, the 2003 Medicare Modernization Act contains requirements for safety requirements built into any such program.
Official actions and statements
November 2022: FDA denies the application.
April 2021: New Hampshire submits an SIP application.
HB1280: Text of the Bill
SB685: Text of the Bill | New Hampshire State Senate hearing
Testimony opposing SB685:
- The Best Medicines Coalition, January 21, 2020
- The Partnership for Safe Medicines, January 2020
Background / resources
Learn more about
Op-eds from the Experts
Pharmacy boards, which ensure the safety of prescription medicines at the state level, have been sending letters to Congress to expressing significant safety concerns about legislation that would legalize drug importation.
The Salt Lake Tribune printed this editorial by Tom Ridge, the 43rd governor of Pennsylvania and first secretary of the U.S. Department of Homeland Security, on June 10, 2017. Ridge is currently a senior advisor to Americans for Securing All Packages (ASAP).
This editorial was published by the Institute for Policy Innovation on June 5, 2017. Its author, Dr. Merrill Matthews, is a resident scholar with the Institute for Policy Innovation, a health policy expert and contributor at Forbes.com. He also serves on the Texas Advisory Committee of the U.S. Commission on Civil Rights.
Ali Schroer wrote this editorial for the Washington Examiner on May 10, 2017.
Like millions of Americans, I take allergy medicine. A few years ago, my doctor urged me to bid farewell to my local pharmacy and instead buy my medication from an online Canadian drug store, where it was cheaper. What terrible advice! The website was counterfeit and sent me “medicine” that was anything but — causing me to get severely sick . . .
Ronald Piervincenzi, CEO of the U.S. Pharmacopeial Convention describes the dangerous flaws in any plan to open up U.S. borders to wholesale prescription medication importation from Canada.
Pew Trust Warns Senator Sanders that Drug Import Bill Could Compromise the Safety of the U.S. Drug Supply
On Tuesday, February 28, Allan Coukell, Senior Director of Health Programs for the Pew Charitable Trusts, wrote Senator Bernie Sanders to ask that he not undermine safety protections for medication with the Affordable and Safe Prescription Drug Importation Act.
In 2016, the American Medical Association reaffirmed its longheld opposition to drug importation through two policy statements. The first, “Prescription Drug Importation and Patient Safety D-100.983,” supports only the importation of FDA-approved medicines. The second, “Federal Regulation and Computerized Tracking of Pharmaceuticals During Shipping and Handling from Manufacture Until Ultimately Received by Patient D-100.985,” promised to actively oppose drug diversion, illegal importation, and drug counterfeiting.
In May 2004, anesthesiologist and American Medical Association trustee Rebecca J. Patchin, MD spoke before the Department of Health and Human Services Task Force on Drug Importation to express concern about the safety and reliability of imported drugs.
- « Previous